Caglevic, Christian
Fundación Arturo López Pérez
3 papers on CoChatORCID 0000-0003-3319-1678
Most cited papers
- Verified
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 960
- Verified
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology
Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers
Cited by 643
- Verified
Abstract CT035: Pharmacokinetics (PK), safety, and tolerability of pembrolizumab with berahyaluronidase alfa administered subcutaneously Q3W in participants with advanced melanoma
Coetzee, C., Khanyile, R., Cohen, G., McAdam, G., Walton, C., Chan, S. W., Rapoport, B., Caglevic, C., Yañez, P., Lala, M., et al. (2025) · Cancer Research
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 2
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free